bluuebunny/crossref_metadata_2025_split huggingface dataset:
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
Authors: Han Chenglong , Smolen Josef S , Kavanaugh Arthur , van der Heijde Désirée , Braun Jürgen , Westhovens René , Zhao Ning , Rahman Mahboob U , Baker Daniel , Bala Mohan 
Published: October 2007

AbstractIn this study, we compare the health-related quality of life (HRQoL) of patients with moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), and study the effect of treatment with infliximab on the HRQoL of patients with these diseases. Short Form Health Survey-36 (SF-36) data from the placebo-controlled phases of 4 studies of infliximab in patients with inflammatory rheumatic diseases (n = 1990) were evaluated. Data came from the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) (n = 428), the Safety Trial for Rheumatoid Arthritis with REMICADE Therapy (START) (n = 1083), the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) (n = 279), and the Infliximab Multinational Psoriatic Arthritis Clinical Trial II (IMPACT II) (n = 200). SF-36 assessments were made at weeks 0, 10, 30, and 54 in ATTRACT, weeks 0, 6, and 22 in START, weeks 0, 12, and 24 in ASSERT, and weeks 0 and 14 in IMPACT II. All patient populations had significantly impaired physical aspects of HRQoL at baseline relative to the general population of the United States, and the magnitude of impairment was similar across the diseases. Mean baseline physical component summary scores were 29 in the RA cohort, 32 in the PsA cohort, and 29 in the AS cohort. In all 3 diseases, patients who received infliximab showed significant improvement in physical component summary scores compared with those who received placebo. The magnitude of the difference of improvement (effect size, 95%CI) between infliximab and placebo groups was similar in the AS (10.1, 9.2–11.0), PsA (8.6, 7.8–9.4), and RA (10.1, 9.2–11.0) cohorts. Patients with RA and those with PsA treated with infliximab also showed greater improvement in the mental component summary score than those in the placebo group with an effect size of 4.6 (4.2–5.1) in RA and 2.7 (2.4–3.1) in PsA. Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab.
Site of Oncologic Specialty Care for Older Adolescents in Utah
Authors: Albritton Karen H. , Wiggins Charles H. , Nelson Harold E. , Weeks Jane C. 
Published: October 2007

Purpose Adolescents with cancer may access oncologic care from pediatric or adult medical centers, given overlapping age eligibility. However, some recent data suggest a benefit to adolescents with certain cancers when treated at pediatric centers or on pediatric protocols. We used a population-based registry to determine the site of care of children, adolescents, and young adults (age 0 to 24 years) with newly diagnosed cancer. Patients and Methods From the Utah Cancer Registry 1994 to 2000, new malignant cases in patients aged 0 to 24 years were chosen; data including diagnosis, home ZIP code and sites of oncologic care were abstracted. Distance between home ZIP code and Primary Children's Medical Center (PCMC; Salt Lake City, Utah), the state's sole site of pediatric oncology care, was determined. Results Sixty-six percent of Utah 15- to 19-year-olds with cancer were never seen by a PCMC oncologist. Even among this narrow age range, utilization of the pediatric center dropped with each additional year of age. Not unexpectedly, few of those with epithelial malignancies in this age group were seen at PCMC. But surprisingly, 47% of the older adolescents with leukemia, 66% with brain tumors, and 71% with lymphoma never saw a pediatric oncologist. After consideration of age and diagnosis, distance the patient lived from PCMC had a negligible effect on the likelihood of an adolescent being seen there. Conclusion The referral of adolescents with cancer to a pediatric oncology center diminishes greatly with age, and is moderately influenced by diagnosis and minimally by distance from center. Further study should investigate reasons for referral patterns, and impact on outcomes.
Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology
Authors: Riechelmann Rachel P. , Wang Lisa , O'Carroll Aoife , Krzyzanowska Monika K. 
Published: October 2007

Purpose There is concern that financial relationships between sponsors and investigators may bias research results. Our objective was to evaluate the epidemiology of conflicts of interest (COIs) among authors of clinical trials and editorials in oncology and the relationship between COI disclosure and source of funding. Methods We did a cross-sectional survey of clinical trials and editorials of anticancer agents and supportive care medications published in the Journal of Clinical Oncology (JCO) during a 1-year period. Results Of 1,533 articles published in JCO between January 1, 2005, and January 31, 2006, 332 met our inclusion criteria; 289 (87%) were clinical trials, and 43 (13%) were editorials. The pharmaceutical industry entirely or partially funded 44% of the clinical trials. At least one COI was disclosed in 69% of clinical trials and 51% of editorials. The most common types of COI reported by authors were consultancy fees, honoraria, and research funds. The highest monetary levels of interest reported by authors were for research grants, but the majority of authors with COIs received less than US$10,000. In multivariable analysis, authors of clinical trials conducted in North America (North America v Europe: odds ratio [OR] = 2.9, P = .002) and authors of trials funded entirely (industry only v nonprofit: OR = 13.8, P < .001) or partially (both industry and nonprofit v nonprofit only: OR = 5.8, P < .001) by industry were more likely to report personal COIs. Conclusion COIs are common in clinical cancer research and usually take the form of consultancy fees, honoraria, and research funds. Source of study funding was significantly associated with COI disclosure.
Glycosylation and Malonylation of Quercetin, Epicatechin, and Catechin by Cultured Plant Cells
Authors: Shimoda Kei , Otsuka Takanao , Morimoto Yoko , Hamada Hatsuyuki , Hamada Hiroki 
Published: October 2007

Abstract
Quercetin was converted to quercetin 3-O-(6-O-malonyl)-β-d-glucoside through the regioselective glucosylation at 3-position of quercetin and the following regioselective malonylation at 6-position of sugar moiety of quercetin 3-O-β-d-glucoside with cultured Nicotiana tabacum cells. On the other hand, N. tabacum cells glucosylated epicatechin and catechin to the corresponding 3′-, 5-, and 7-O-β-d-glucosides, respectively.
Reaction of Copper(II) Complexes with Na2S2. An Alternative Method for the Preparation of Disulfido–Dicopper(II) Complexes
Authors: Inosako Masayuki , Shimokawa Chizu , Sugimoto Hideki , Kihara Nobuhiro , Takata Toshikazu , Itoh Shinobu 
Published: October 2007

Abstract
The reaction of copper(II) complexes supported by β-diketiminate ligands with Na2S2 has been examined as an alternative method for the preparation of (μ-η2:η2-disulfido)dicopper(II) complexes.
A Novel Negative-working Photoimaging Material Based on a Base-amplifying Silicone Resin Tethering Phenylsulfonylethyl Groups
Authors: Inoue Satoru , Arimitsu Koji , Abe Yoshimoto , Ichimura Kunihiro 
Published: October 2007

Abstract
We have developed a base-sensitive silicone resin tethering phenylsulfonylethyl units as base-amplifying groups showing high thermal stability. The resin underwent a base proliferation reaction autocatalytically to generate amino groups on its side chains, which accelerated the base-catalyzed hydrolytic condensation of residual ethoxysilyl units in its main chain. Furthermore, a film of the resin sensitized with a photobase generator provided a negative-working photoimaging material with a high sensitivity.
Reversible Immobilization of Protein into Hydrogel Using Designed Coiled-coil Peptides
Authors: Murota Kazutoshi , Sakamoto Seiji , Kudo Kazuaki 
Published: October 2007

Abstract
By using a heteromeric coiled-coil interaction between peptides, both immobilization of a protein into polymer hydrogel and an efficient release of the protein from the hydrogel were achieved.
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States
Authors: Delea Thomas E. , Hagiwara May , Thomas Simu K. , Baladi Jean‐Francois , Phatak Pradyumna D. , Coates Thomas D. 
Published: October 2007

AbstractDeferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload. Data on the utilization and costs of care among U.S. patients receiving DFO in typical clinical practice are limited however. This was a retrospective study using a large U.S. health insurance claims database spanning 1/97–12/04 and representing 40 million members in >70 health plans. Study subjects (n = 145 total, 106 sickle cell disease [SCD], 39 thalassemia) included members with a diagnosis of thalassemia or SCD, one or more transfusions (whole blood or red blood cells), and one or more claims for DFO. Mean transfusion episodes were 12 per year. Estimated mean DFO use was 307 g/year. Central venous access devices were required by 20% of patients. Cardiac disease was observed in 16% of patients. Mean total medical costs were $59,233 per year including $10,899 for DFO and $8,722 for administration of chelation therapy. In multivariate analyses, potential complications of iron overload were associated with significantly higher medical care costs. In typical clinical practice, use of DFO in patients with thalassemia and SCD receiving transfusions is low. Administration costs represent a large proportion of the cost of chelation therapy. Potential complications of iron overload are associated with increased costs. Am. J. Hematol., 2008. © 2007 Wiley‐Liss, Inc.
Phase behavior on the binary and ternary mixtures of poly(isooctyl acrylate) + supercritical fluid solvents + isooctyl acrylate and CO2 + isooctyl acrylate system
Authors: Byun Hun‐Soo , Park Young‐Jin , Lim Jong‐Sung 
Published: October 2007

AbstractExperimental cloud‐point data to the temperature of 180 °C and the pressure up to 2000 bar are presented for ternary mixtures of poly(isooctyl acrylate) + supercritical fluid solvents + isooctyl acrylate systems. Cloud‐point pressures of poly(isooctyl acrylate) + CO2 + isooctyl acrylate system is measured in the temperature range of 60–180°C and to pressures as high as 2000 bar with isooctyl acrylate concentration of 0–44.5 wt. This system changes the pressure–temperature slope of the phase behavior curves from upper critical solution temperature (UCST) region to lower critical solution temperature (LCST) region as the isooctyl acrylate concentration increases. Poly(isooctyl acrylate) does dissolve in pure CO2 to the temperature of 180°C and the pressure of 2000 bar. The phase behavior for poly(isooctyl acrylate) + CO2 + 9.5, 14.8, 30.6, and 41.9 wt % dimethyl ether (DME) mixture show the curve changes from UCST to LCST as the DME concentration increases. Also, the cloud‐point curves are measured for the binary mixtures of poly(isooctyl acrylate) in supercritical propane, propylene, butane, and 1‐butene. High pressure phase behaviors are measured for the CO2 + isooctyl acrylate system at 40, 60, 80, 100, and 120°C and pressure up to 200 bar. This system exhibits type‐I phase behavior with a continuous mixture‐critical curve. The experimental results for the CO2 + isooctyl acrylate system are modeled using the Peng‐Robinson equation of state. © 2007 Wiley Periodicals, Inc. J Appl Polym Sci 2008
Structure of polycondensates from hydroxymethylphenols
Authors: Christjanson Peep , Pehk Tõnis , Siimer Kadri , Paju Jane 
Published: October 2007

AbstractThe structure of oligomers obtained from mono‐hydroxymethylphenols in melt condensation at 120°C was determined using 13C NMR spectra in CD3OD solution. Alongside of methylene region of spectrum, valuable information was obtained from signals of aromatic carbons. Noncatalytic conditions promote the formation of dihydroxydibenzyl ethers in equilibrium with ortho‐ and para‐benzoquinones of oxymethylene derivatives. The final methylene linked oligomers are formed, mainly, by splitting the ether intermediates with free aromatic positions. In alkaline conditions, highly nucleophilic phenoxide ions of ortho‐hydroxymethyl compounds are responsible for substitution in free aromatic positions. The most favored reaction in the mixture of both hydroxymethylphenols is the formation of p,p′‐methylene. In condensation of para‐hydroxymethylphenol, formation of p,p′‐methylene groups occurs with simultaneous release of formaldehyde. High content of alkali stabilized ortho‐hydroxymethyl groups of fully substituted methylene linked oligomers determines the curing behavior of resol phenol–formaldehyde resins. The role of hemiformals in reactions was insignificant. © 2007 Wiley Periodicals, Inc. J Appl Polym Sci 2008
Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia
Authors: Hinds Pamela S. , Hockenberry Marilyn J. , Gattuso Jami S. , Kumar Srivastava Deo , Tong Xin , Jones Heather , West Nancy , McCarthy Kathy S. , Sadeh Avi , Ash Monica , Fernandez Cheryl , Pui Ching‐Hon 
Published: October 2007

AbstractBACKGROUND.Dexamethasone improves the cure rate of childhood acute lymphoblastic leukemia (ALL) but causes physical and behavioral adverse events. The objective of the current study was to determine the effect of dexamethasone exposure on sleep and fatigue in pediatric patients with ALL.METHODS.One hundred pediatric patients with low‐risk or standard‐risk ALL were enrolled on 1 of 3 protocols (St. Jude Total XV, Children's Oncology Group [COG] 9904, or COG 9905) at 3 institutions. The mean age of the cohort was 9.24 ± 3.23 years (range, 5.03‐18.14 years). The majority of patients were white (79%) males (62%) with standard‐risk ALL (63%). The cohort was divided into 4 subgroups: St. Jude low‐risk, St. Jude standard‐risk, COG low‐risk, and COG standard‐risk. Patients wore a wrist actigraph to monitor sleep activity during 2 consecutive 5‐day periods: During the first period, they did not receive dexamethasone; and, during the second period, they did. Patients and their parents completed fatigue instruments on Days 2 and 5 of each period, and parents completed sleep diaries.RESULTS.Actual sleep minutes, sleep duration, total daily nap minutes, and fatigue increased significantly during the dexamethasone treatment for 3 to 4 of the subgroups. Total daily nap minutes increased significantly for both standard‐risk groups during the dexamethasone treatment. Parents reported significant increases in their child's nighttime awakenings, restless sleep, and nap time during dexamethasone treatment.CONCLUSIONS.Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone. 2007. © 2007 American Cancer Society.
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor‐positive metastatic breast cancer: A confirmatory prospective study
Authors: Colomer Ramon , Llombart‐Cussac Antonio , Lloveras Belen , Ramos Manuel , Mayordomo Jose I. , Fernández Roberto , Tusquets Ignasi , Gil Miguel , Barnadas Agustí , Constenla Manuel , Gilabert Montserrat , Alba Emilio 
Published: October 2007

AbstractBACKGROUND.In this specifically designed, prospective study, the authors addressed the predictive value of circulating levels of the extracellular domain (ECD) of HER2 in patients with metastatic breast cancer who were treated with letrozole.METHODS.Two hundred twenty‐six patients with hormone receptor‐positive, metastatic breast cancer received letrozole (2.5 mg daily) until they developed either disease progression or unacceptable toxicity. Efficacy was measured primarily as the time to progression (TTP) and, secondarily, as the objective response rate (ORR) and overall survival. HER2 ECD levels were determined by using a sandwich enzyme HER2/neu immunoassay before letrozole treatment was initiated. Positive HER2 ECD status was correlated with treatment efficacy.RESULTS.Forty‐two patients (19%) had elevated HER2 ECD levels, which were associated with primary tumor HER2 expression (P < .001) but not with age, performance status, location, or number of metastatic sites. The median TTP was significantly shorter among patients who had elevated HER2 ECD compared with the median TTP among patients who had normal levels (4 months vs 14 months; P = .0004), and the ORR was lower in the group with elevated HER2 ECD levels (14% vs 30%; P < .036). Overall survival was significantly shorter among patients with elevated serum HER‐2 ECD (P < .0005).CONCLUSIONS.Elevated HER2 ECD concentrations predicted poorer outcomes in postmenopausal women with metastatic hormone receptor‐positive breast cancer who were treated with aromatase inhibitors like letrozole. © 2007 American Cancer Society.
Differential expression of HNK‐1 and p75NTR in adult canine Schwann cells and olfactory ensheathing cells in situ but not in vitro
Authors: Bock Patricia , Beineke Andreas , Techangamsuwan Somporn , Baumgärtner Wolfgang , Wewetzer Konstantin 
Published: October 2007

AbstractOlfactory ensheathing cells (OECs) are promising candidates for autologous cell transplantation therapies of nervous system injury and disease. Large animal models are relevant for transferring experimental data into clinical practice. In vivo studies have suggested that adult canine OECs may display similar regenerating capacities as their rodent counterpart. However, data on their molecular phenotype required for generating pure cell preparations are still scarce. In the present study, we comparatively analyzed expression of the carbohydrate HNK‐1 epitope and the neurotrophin receptor p75NTR in adult canine Schwann cells and olfactory ensheathing cells in situ and in vitro. Myelinating and nonmyelinating Schwann cells in situ exclusively expressed HNK‐1 and p75NTR, respectively, whereas OECs were negative for both markers. In vitro, OECs and Schwann cells shared cell surface expression of p75NTR but not of HNK‐1, which could be detected transiently in intracellular vesicles. This suggests that Schwann cells and OECs in vitro phagozytose HNK‐1+ cellular debris. The cultivation‐induced downregulation of HNK‐1 expression in Schwann cells and upregulation of p75NTR in OECs argues for the possibility that axonal signals control the expression of both markers in situ. Whereas HNK‐1 expression in Schwann cells is most likely controlled by signals inducing myelination, e.g., neuregulin, the mechanisms that may suppress p75NTR expression in OECs in situ remain to be elucidated. Interestingly, HNK‐1 expression in the adult dog was found in both sensory and motor nerve myelinating Schwann cells. This is reminiscent of humans and differs from rodents; it also underscores the importance of large animal models for translational research. J. Comp. Neurol. 505:572–585, 2007. © 2007 Wiley‐Liss, Inc.
Synthesis, Structure and a DFT/TDDFT Study of a Diimido‐Bridged Asymmetric Dimolybdenum Complex
Authors: Pal Kuntal , Sarkar Sabyasachi 
Published: October 2007

AbstractThe homobimetallic complex (Bu4N)2[MoO(mnt)Mo{o‐aminobenzothiolato(3–)‐N,S}2(mnt)] (2; mnt = 1,2‐dicyanoethylenedithiolate) has been synthesized as a dark green solid by treating (Bu4N)2[Mo2O4(mnt)2] (1) with o‐aminothiophenol in CH3CN. An X‐ray crystal structure analysis of 2 reveals that it possesses an asymmetric structure where one Mo has a distorted octahedral geometry and the other a square‐pyramidal geometry. The basal plane of the two Mo centers makes an angle of 26.41°, which is nearly one quarter of 90°. The shape of the ν(Mo=O) band in the IR spectrum of 2 suggests that these Mo atoms may have different oxidation states. The different reactivity of 1 with o‐aminothiophenol and 2‐aminoethanethiol was followed by EPR spectroscopy, and analysis of the different end‐products from these reactions supports the proposal that 2 is a mixed‐valence compound containing MoVI and MoIV centers. The electronic structures of 1 and 2 have been calculated at the DFT level of theory to analyse the effect of a deviation of the basal plane on the metal–metal bond in 2. The cyclic voltammetric responses of 1 and 2 have been measured to correlate the data with the computational results. TDDFT calculations have been performed on 1 and 2 in the gas phase and also in a solvent medium to assign the transitions corresponding to the peaks found in the respective experimental electronic absorption spectra of these complexes.(© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)
Order imbalance and the dynamics of index and futures prices
Authors: Fung Joseph K.W. , Yu Philip L.H. 
Published: October 2007

AbstractThis study uses transaction records of index futures and index stocks, with bid/ask price quotes, to examine the impact of stock market order imbalance on the dynamic behavior of index futures and cash index prices. Spurious correlation in the index is purged by using an estimate of the “true” index with highly synchronous and active quotes of individual stocks. A smooth transition autoregressive error correction model is used to describe the nonlinear dynamics of the index and futures prices. Order imbalance in the cash stock market is found to affect significantly the error correction dynamics of index and futures prices. Order imbalance impedes error correction particularly when the market impact of order imbalance works against the error correction force of the cash index, explaining why real potential arbitrage opportunities may persist over time. Incorporating order imbalance in the framework significantly improves its explanatory power. The findings indicate that a stock market microstructure that allows a quick resolution of order imbalance promotes dynamic arbitrage efficiency between futures and underlying stocks. The results also suggest that the unloading of cash stocks by portfolio managers in a falling market situation aggravates the price decline and increases the real cost of hedging with futures. © 2007 Wiley Periodicals, Inc. Jrl Fut Mark 27:1129–1157, 2007
Transactions in futures markets: Informed or uninformed?
Authors: Frino Alex , Kruk Jennifer , Lepone Andrew 
Published: October 2007

AbstractUsing a proprietary data set from the Sydney Futures Exchange, this study reconciles an inconsistency in futures microstructure literature. One strand of the literature documents that single trades in futures markets contain information, whereas another strand finds that trade packages in futures markets do not contain information. This study controls for methodological and sample differences in examining the price impact of individual trades and trade packages. We find little evidence that transactions in futures markets contain information. © 2007 Wiley Periodicals, Inc. Jrl Fut Mark 27:1159–1174, 2007